VIEW ALL RESEARCH-GROUP

Metabolism and cancer
Menendez’s Lab

DESCRIPTION

Unlocking the metabolic secrets of cancer: Our “Metabolism and Cancer” team studies how cellular metabolism drives cancer growth, drug resistance, and metastasis. We use cutting-edge laboratory experiments, computational tools and clinical trials to validate our discoveries in cancer patients.

MAIN RESEARCH LINES

  1. CANCER METABOLISM

    Metabolic inhibitors for cancer therapy

    • Metabolic mechanisms of tumorigenesis & drug resistance
    • Clinical development of anti-cancer metabolic drugs

    Mitochondria, senescence, and cancer

    • Mitochondria-based elimination of tumor-/metastasis-initiating cells
    • Metabolic therapy-induced senescence (MTIS)

    Metabolo-immunotherapy

    • Tumor cell-intrinsic immunometabolism 
    • Metabolic/dietary interventions and immunotherapy 
  2. BIOCOMPOUNDS
    • Natural biocompounds for cancer treatment
  3. COMPUTATIONAL BIOLOGY & CHEMISTRY
    • Mathematical modeling of cancer
    • Computational design of anti-cancer metabolic drugs

Javier A. Menendez

Group leaders

IP

Elisabet Cuyàs

Researchers

Established researcher (Miguel Servet)

Eila Serrano Hervás

Researchers

Postdoctoral researcher (INVESTIGO)

Sara Verdura

Researchers

Predoctoral researcher

Àngela Llop Hernández

Young investigators

Predoctoral researcher

Júlia López

Young investigators

Predoctoral researcher

Begoña Martín Castillo

Researchers

Established researcher (Unit of Clinical Research, ICO-Girona)

Eugeni López Bonet

Researchers

Established researcher (Hospital Trueta)

Sensory Features Introduced by Brewery Spent Grain with Impact on Consumers’ Motivations and Emotions for Fibre-Enriched Products

/in /by

Foods. 2021 Dec 24;11(1):36. doi: 10.3390/foods11010036. ABSTRACT The aim of this work was both to formulate three different fibre-enriched products by the addition of Brewery Spent Grain (BSG), and to evaluate the impact of this fibre enrichment on sensory quality, acceptability, and purchase intention under blind conditions. BSG was incorporated into bread, pasta, and chocolate […]

Fatty acid synthase (FASN) regulates the mitochondrial priming of cancer cells

/in /by

Cell Death Dis. 2021 Oct 21;12(11):977. doi: 10.1038/s41419-021-04262-x. ABSTRACT Inhibitors of the lipogenic enzyme fatty acid synthase (FASN) have attracted much attention in the last decade as potential targeted cancer therapies. However, little is known about the molecular determinants of cancer cell sensitivity to FASN inhibitors (FASNis), which is a major roadblock to their therapeutic […]

Whey-Derived Porous Carbon Scaffolds for Bone Tissue Engineering

/in /by

Biomedicines. 2021 Aug 26;9(9):1091. doi: 10.3390/biomedicines9091091. ABSTRACT Porous carbon structures derived from whey powders are described and evaluated as potential scaffolds in bone tissue engineering. These materials have a porosity between 48% and 58%, with a hierarchical pore size distribution ranging from 1 to 400 micrometres. Compressive strength and elastic modulus are outstanding for such […]

Ultralight-Weight Graphene Aerogels with Extremely High Electrical Conductivity

/in /by

Small. 2021 Oct;17(41):e2103407. doi: 10.1002/smll.202103407. Epub 2021 Sep 12. ABSTRACT The integration of 2D graphene sheets into a porous and macroscopic structure is extremely attractive for application in several electrochemical fields. In this regard, for the first time, the synthesis of 3D graphene aerogels is reported by using a rapid, easy, cost-effective, and scalable at […]

Silibinin Suppresses Tumor Cell-Intrinsic Resistance to Nintedanib and Enhances Its Clinical Activity in Lung Cancer

/in /by

Cancers (Basel). 2021 Aug 19;13(16):4168. doi: 10.3390/cancers13164168. ABSTRACT The anti-angiogenic agent nintedanib has been shown to prolong overall and progression-free survival in patients with advanced non-small-cell lung cancer (NSCLC) who progress after first-line platinum-based chemotherapy and second-line immunotherapy. Here, we explored the molecular basis and the clinical benefit of incorporating the STAT3 inhibitor silibinin-a flavonolignan […]

Ruth Lupu | Mayo Clinic, Rochester, USA

Pilar Blancafort | Harry Perkins Institute of Medical Research, Perth, Australia

Francesca Cutruzzolà | Sapienza University, Rome, Italy

Tomás Alarcón | ICREA-Centre de Recerca Matemàtica (CRM), Reus, Spain

Sílvia Osuna | ICREA-Institut de Química Computacional i Catàlisi (IQCC), Girona, Spain

Josep Sardanyés | Centre de Recerca Matemàtica (CRM), Barcelona, Spain

José Antonio Encinar | Universidad Miguel Hernández, Elche, Spain

Vicente Micol | Universidad Miguel Hernández, Elche, Spain

Antonio Segura-Carretero | Universidad de Granada, Granada, Spain

Jorge Joven | Institut d’Investigació Sanitària Pere Virgili (IISPV), Reus, Spain

Carlos Peña Garay | Laboratorio Subterráneo de Canfranc (LSC), Spain

Menendez grup. Research group photo
Program Against Cancer Therapeutic Resistance

CONTACT US

Campus IDIBELL
(L’Hospitalet del Llobregat)
Hospital Duran i Reynals, Gran Via 199,
L’Hospitalet del Llobregat,
Barcelona 08908
Tel. +34 93 260 7952

Campus IGTP-IJC
(Badalona)
Campus Can Ruti – IGTP – Building Muntanya,
Rd. Can Ruti, Camí de les escoles s/n,
Badalona, Barcelona 08916
Tel. +34 93 554 3069

Campus IDIBGI
(Girona)
Parc Hospitalari Martí i Julià de Salt, Dr. Castany s/n,
Salt, Girona 17190
Tel. +34 872 987 087

Pujana’s LabPujana's LabGrup-Hematoligia-webSureda’s & Farre’s Lab